The National Institute on Drug Abuse (NIDA) has announced its intent to publish a Notice of Funding Opportunity (NOFO) for an Annual Conference in Therapeutics Development for Substance Use Disorders (U13 Clinical Trial Not Allowed). This initiative is designed to support the planning, organization, and implementation of an annual scientific meeting focused on advancing the development of therapeutics for substance use disorders (SUDs). The NOFO will utilize the U13 cooperative agreement mechanism.
The purpose of this program is to facilitate scientific exchange, foster collaboration, and promote innovation in the field of SUD therapeutics. The annual conference will bring together researchers, clinicians, policymakers, and other stakeholders to discuss challenges, share advancements, and identify opportunities in developing and implementing effective treatments for SUDs. The program emphasizes the importance of disseminating knowledge and catalyzing progress in this critical area of public health.
Eligible applicants include a wide range of entities, such as public and private institutions of higher education, state and local governments, Native American tribal entities, nonprofits with 501(c)(3) status, independent school districts, small businesses, for-profit organizations other than small businesses, and public or Indian housing authorities. This broad eligibility ensures participation from diverse organizations with a vested interest in addressing SUDs.
The NOFO is expected to be published in December 2024, with applications due by February 20, 2025. The award is anticipated to be announced by December 1, 2025, and the funded project is scheduled to begin on the same day. Potential applicants are encouraged to begin organizing partnerships and outlining proposals to align with the program's objectives.
Evaluation criteria will likely include the applicant’s capacity to organize and manage a high-impact scientific meeting, the relevance and significance of the proposed conference topics to SUD therapeutics development, and the potential for fostering collaboration and innovation. Applications should provide a detailed plan for conference activities, including logistics, topics, and expected outcomes. Specific requirements and submission instructions will be detailed in the forthcoming NOFO.
The total estimated program funding is $100,000, with a maximum award ceiling of $100,000. Cost-sharing or matching funds are not required, which allows applicants to focus resources on conference planning and execution. Only one award is expected to be made under this NOFO.
This opportunity offers a platform to shape the future of SUD therapeutics by facilitating discussions and collaboration among key stakeholders. Interested organizations should monitor Grants.gov and related communications for updates and detailed guidance as the application period approaches.
